B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 52
Inquire Before Buying

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
B-Cell Chronic Lymphocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 8
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies 10
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Development by Companies 15
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 17
Genzyme Corporation 17
Abbott Laboratories 18
GTC Biotherapeutics, Inc. 19
Ono Pharmaceutical Co., Ltd. 20
Alexion Pharmaceuticals, Inc. 21
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
samalizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Campath + Fludara - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
alvocidib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alvocidib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
alvocidib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alvocidib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABT-263 + Rituximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Leukapheresis + Fludarabine + Cyclophosphamide + Autologous CD19 Specific T-cell Infusion - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
cediranib maleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ABT-348 + Azacitidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ONO-4059 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-CD 19 CAR Autologous PBL - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 49
Featured News & Press Releases 49
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 49
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Genzyme Corporation, H2 2012 17
Abbott Laboratories, H2 2012 18
GTC Biotherapeutics, Inc., H2 2012 19
Ono Pharmaceutical Co., Ltd., H2 2012 20
Alexion Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Current State of Blood Banking Market, Products, Technologies and Services
    The global blood banking and blood products market is expected to reach US$41.9 billion by 2020 with USA continuing to be the largest market worldwide. Asia-Pacific follows a close second with a projected CAGR of 9.1% during this period owing to the refining healthcare infrastructure and increase in the per capita healthcare expenditure. The major [...]
  • Surgical Robots Market 2016 Updates on Companies, Products and More
    Surgical robots are medical devices that assist surgeons in performing many types of complex procedures with more accuracy, flexibility and control than is possible with conventional techniques. The aim of surgical robots market players is to provide improved diagnostic skills, a less invasive and more comfortable experience for the patient, and the ability to do [...]
  • Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016
    Published: 04-Jul-2016        Price: US 1750 Onwards        Pages: 179
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Estrogen Receptor Positive (ER+) Breast Cancer. The report provides the in-depth analysis of the pipeline assets ......
  • Ovarian Cancer-Pipeline Insights, 2016
    Published: 04-Jul-2016        Price: US 2250 Onwards        Pages: 260
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Ovarian Cancer -Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer form......
  • Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023_United States
    Published: 04-Jul-2016        Price: US 3250 Onwards        Pages: 60
    Note: This report will be delivered to the client in 48 hours DelveInsight's "Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023- US" Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) B......
  • Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020-US
    Published: 04-Jul-2016        Price: US 3250 Onwards        Pages: 60
    Note: This report will be delivered to the client in 48 hours DelveInsight's "Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US" Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer from 2012-2020. According to DelveInsight, the forecasted patient population of Ova......
  • Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016
    Published: 04-Jul-2016        Price: US 2450 Onwards        Pages: 90
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to......
  • Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016
    Published: 04-Jul-2016        Price: US 2450 Onwards        Pages: 90
    Note: This report will be delivered to the client in 48 hours DelveInsight's, "Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the ovarian cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and comp......
  • Global Mucositis Partnering 2010-2016
    Published: 01-Jul-2016        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access t- the mucositis partnering deals and agreements entered int- by the worlds leading healthcare companies The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access t- partnering deals and agreements entered int- by the world's leading healthcare companies. - Trends in partnering deals......
  • Global Breast Cancer Partnering 2010 to 2016
    Published: 01-Jul-2016        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Summary Provides comprehensive understanding and unprecedented access t- breast cancer partnering deals and agreements entered int- by the worlds leading healthcare companies. The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access t- partnering deals and agreements entered int- by the world's leading healthcare companies. ......
  • Global Bladder Cancer Partnering 2010 to 2016
    Published: 01-Jul-2016        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access t- the bladder cancer partnering deals and agreements entered int- by the worlds leading healthcare companies The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access t- partnering deals and agreements entered int- by the world's leading healthcare companies. - Trends in partnering......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs